Rationale: Clinical and real-world studies show that elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is efficacious and safe in people with cystic fibrosis (CF)
- Daines, C. L.
- Polineni, D.
- Tullis, E.
- Costa, S.
- Linnemann, R. W.
- Mall, M. A.
- McKone, E. F.
- Quon, B. S.
- Ringshausen, F. C.
- Selvadurai, H.
- Taylor-Cousar, J. L.
- Withers, N. J.
- Sawicki, G. S.
- Lee, T.
- Ahluwalia, N.
- Morlando Geiger, J.
- Jennings, M.
- Tan, Y. V.
- Waltz, D.
- Ramsey, B.
- Griese, M.
Keywords
- Humans
- *Cystic Fibrosis/drug therapy/genetics
- Male
- *Quinolones/therapeutic use/adverse effects/administration & dosage
- *Aminophenols/therapeutic use/adverse effects/administration & dosage
- Female
- Adult
- Adolescent
- *Benzodioxoles/therapeutic use/adverse effects/administration & dosage
- *Indoles/therapeutic use/adverse effects/administration & dosage
- Drug Combinations
- *Cystic Fibrosis Transmembrane Conductance Regulator/genetics
- Young Adult
- Treatment Outcome
- Child
- *Pyrazoles/therapeutic use/adverse effects
- *Pyrrolidines/therapeutic use/adverse effects
- *Pyridines/therapeutic use/adverse effects
- Chloride Channel Agonists/therapeutic use
- Alleles
- Middle Aged
- Genotype
- *Quinoxalines/therapeutic use/adverse effects
- Quinolines
- cystic fibrosis
- elexacaftor
- ivacaftor
- long-term
- tezacaftor
